Do you want to read an article? Please log in or register.
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
Further Publications
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
Ann Oncol
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G
doi: 10.1016/j.annonc.2025.03.019
Lung, Respiratory and Thoracic Cancer
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data
Lung Cancer
Gemelli M, Cortinovis D, Carola G, Moretti L, Piazza F, Calza S, Ricotta R, Grisanti S, Rota M
doi: 10.1016/j.lungcan.2025.108621
Gastrointestinal Cancer
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study
Eur J Cancer
Campo-Le-Brun I, Grapinet E, Aurillac V, Hollebecque A, Parent P, Girot P, Tougeron D, Gendreau M, Chanez B, Assenat E, Pernot S, Alouani E, Taieb J, Javed S, Touchefeu Y, Roth G, Muller M, Bachet JB, Lequoy M, Hautefeuille V, Ben-Abdelghani M, Masson T, Guimbaud R, Boilève A, Decraecker M
doi: 10.1016/j.ejca.2025.115670
Further Publications
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Blood
Leaf RK, Mones JV, Shenoy T, Warsame M, Beltrami-Moreira M, Panch S, Leavitt AD, Zon RL, Kendall EK, Shahamatdar S, Lim TL, Cui C, Jiang D, Kaunfer SA, Durai L, Hoge ST, Dias JA, Sha C, Holmes A, Easton N, Corley E, Zhao E, Li X, Spelman A, Amos CB, Soebbing DR, Shabih M, Jamison T, Liu B, Hussein G, Yadav SK, Elsaid MI, Owen DH, Mera A, Juras PK, Suresh A, Heskel MJ, Huang JJ, Glezerman I, Go RS, Reynolds K, Al-Samkari H, Kroll MH, Leaf DE
doi: 10.1182/blood.2025031449
Lung, Respiratory and Thoracic Cancer
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer
Clin Cancer Res
Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM
doi: 10.1158/1078-0432.CCR-24-2990
Lung, Respiratory and Thoracic Cancer
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens
Lung Cancer
Sugai M, Amino Y, Fujishima S, Nibuya K, Iso H, Ito M, Tsugitomi R, Ariyasu R, Uchibori K, Yanagitani N, Nishio M
doi: 10.1016/j.lungcan.2025.108555
Lung, Respiratory and Thoracic Cancer
Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis
Lung Cancer
Iglesias Martinez B, Insa A, Cervera Ygual G, Gascón F, Domínguez Moran JA, Martín-Martorell P
doi: 10.1016/j.lungcan.2025.108464
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis
Lung Cancer
Zhang Y, Zhao J, Ma Z, Yi J, Yuan Y, Lang L, Zhang C, Zhu M, Zhang Y
doi: 10.1016/j.lungcan.2025.108700